Phillip A. Dennis

AVEO Oncology (United States) — United States

Medicine · Health Sciences

58h-index25.4kcitations307works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(115), Lung Cancer Treatments and Mutations(85), PI3K/AKT/mTOR signaling in cancer(74), Cancer Genomics and Diagnostics(45), Cytokine Signaling Pathways and Interactions(34)

Publications307 total

Molecular Biological Tools for Monitoring Selenium Reduction in Mine-Influenced Water
2024
Abstract 2389: Empowering early drug development in neoadjuvant non-small cell lung cancer studies using an innovative proof-of-concept platform trial design
Cancer Research·2024
Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia
International Journal of Oncology·2023· 7 citedOpen Access
CD-20-0047R2_Supplementary_Figure_2.pdf from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
2023Open Access
Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Data from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
2023Open Access
Supplementary Figure S12 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Data from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Table S4 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
CD-20-0047R2_Supplementary_Figure_1.pdf from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
2023Open Access
Supplementary Figure S9 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Data from Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling
2023Open Access
Data from Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells
2023Open Access
Supplementary Figures 1 and 2 from Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
2023Open Access
Supplementary Figure S1 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Perspectives on This Article from Nicotine Does Not Enhance Tumorigenesis in Mutant <i>K</i>-<i>Ras</i>–Driven Mouse Models of Lung Cancer
2023Open Access
page 1 of 16Next →

Frequent Co-authors

Joell J. Gills(10), Kip A. West(8), Junji Tsurutani(8), Regan M. Memmott(7), Courtney A. Granville(7), John Brognard(6), Amy S. Clark(6), M. Christine Hollander(6), Byoung Chul Cho(5), Jhanelle E. Gray(5), Jaclyn LoPiccolo(5), Scott Antonia(4), Augusto Villegas(4), Davey B. Daniel(4), Shuji Murakami(4), Rina Hui(4), Alberto Chiappori(4), Ki Hyeong Lee(4), Catherine Wadsworth(4), Mustafa Özgüroğlu(4)